Agata Boxe

The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.

Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.